Description overdue on 06.04.2012

Antifungal agent . The active component is fluconazole . Mikos inhibits fungal enzymes that are directly dependent on cytochrome P450 has a high specificity of the election. The drug has no effect on human cytochrome P450 enzyme. It is based on a breach of growth, replication, the permeability of the cell membrane, blocking the transition lanosterol to ergosterol. The basic substance does not have antiadrogennogo influence . The drug is active against opportunistic fungal infections . Mikosist produced in the form of syrup, capsule, suspensions, powders, solutions.

Indications:

Mikosist prescribed for systemic fungal attack: sepsis Meningitis, with immunosuppression for prophylaxis cryptococcal lesions in patients with AIDS . The drug is effective in generalized form of candidiasis: disseminated candidiasis,   candidemia. The drug is indicated for vaginal candidiasis, balanitis, mycosis of the skin, deep endemic mycoses.

Contraindications:

Mikosist not indicated in pregnancy, liver pathology system, intolerance, simultaneous administration of hepatotoxic agents, breastfeeding, allergies to azole antifungals. Be wary appointed in pediatric practice.

Side effect:

The digestive tract:   disorders of the liver, constipation , Diarrhea, nausea, loss of appetite, abdominal pain, flatulence, hyperbilirubinemia . Nervous system:   cramps, fatigue, dizziness, headache. Perhaps the development of hypokalemia, toxic epidermal necrosis, agranulocytosis, leukopenia, alopecia, hypertriglyceridemia, anaphylactoid reactions .

Overdose:

Manifested paranoid phenomena . hallucinations . Treatment for posindromnoe, effective forced diuresis . hemodialysis .

Mode of application:

Mikosist administered intravenously, is taken orally. When anvazivnyh candidiasis, disseminated candidiasis, candidemia, cryptococcal infections: the first day of therapy of 400 mg in the next few days - at 200-400mg a day. Prevention cryptococcal meningitis in AIDS patients: 200 mg a day. Oropharyngeal candidiasis: 7-10 days at 50-100 mg per day. In the pathology of the renal system reduce the dosage.

Special instructions:

The antifungal treatment is carried out to counter clinical remission. When the premature lifting of the drug increases the risk of Mikosist relapse . During therapy, monitor the condition of the liver, blood and kidneys. In case of violations in the work of antifungal therapy is stopped. Hepatotoxic effect of the drug is only temporary. When concomitant administration of coumarin anticoagulants should be assessed prothrombin index .

Drug Interactions:

Mikosist increases activity coumarin anticoagulants , Concentration rifabutin , Zidovudine, cyclosporine, phenytoin. In appointing hydrochlorothiazide   fluconazole concentration in blood increases by 40 percent. Tsazprid and terfenadine may cause arrhythmias during antifungal therapy.